ArticleTranslational pediatrics2025
Immunophenotyping in diagnosing pediatric acute leukemia after setting up the first flow cytometry unit in Mosul City in Iraq: an observational study of the project performed through a contribution from Japan.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrating immunophenotyping and morphology in the diagnosis of acute leukemia at the National Oncology Center, Sana'a, Yemen.The Libyan journal of medicine · 2026Article
- Clinical outcomes in pediatric acute lymphoblastic leukemia: a retrospective cohort study from a tertiary center in Indonesia.Frontiers in pediatrics · 2026Article
- Development and validation of a prognostic prediction model based on coagulation-related genes and clinical factors in acute leukemia.Translational pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Flow cytometry (FCM) is a powerful tool for classifying acute leukemia (AL) to acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) and further subtyping. Accurate diagnosis of AL improves the outcome. Mosul, a city in Iraq, had no FCM laboratory yet, mainly due to repeated wars in the area. The Japan Chernobyl Foundation (JCF), a Japanese non-profit humanitarian organization, helped establish the first FCM Laboratory in Mosul. We aimed to evaluate the project from a scholarly point of view with a focus on childhood ALL. Methods: An observational study was done after JCF provided the BD FACSCanto II system and all related materials. Anonymous data of the patients, including age, sex, address, initial complete blood count (CBC) with bone marrow aspirate (BMA) results, and coded FCM reports, were prospectively collected from February 2021 to January 2024. In addition to clinical notes on pediatric ALL cases, their treatment, and outcomes with a median follow-up of 26.2 (range, 0-44.3) months. Results: Childhood ALL cases were 76, including (60, 78.9%) B-lineage ALL (B-ALL) and (16, 21.1%) T-lineage ALL (T-ALL) cases. B-ALL cases were classified as pro-B, common-B, pre-B, and mature-B, with frequencies of 11.7%, 76.7%, 10.0%, and 1.6%, respectively. T-ALL included early T-cell precursor (ETP), pro-T, pre-T, cortical-T, and medullary-T, with frequencies of 6.25%, 18.75%, 18.75%, 31.25%, and 25.00%, respectively. Furthermore, 20 pediatric AML cases were identified and sub-typed. Among ALL cases, the male-to-female ratio (M/F) was 1.5. There were 24 (31.6%) cases with white blood cell (WBC) counts of ≥50×10 Conclusions: JCF's role was crucial in providing Mosul City, Iraq, with the first FCM Unit. The project made a breakthrough in AL diagnosis and established one of the important and supposed routine steps represented by ALL immunophenotyping. The HR group represented a significantly large portion of our ALL cases. Although the outcome was satisfactory for the SR group, the survival rate for the HR group was dismal. Further efforts are needed to scale up diagnostic and therapeutic capabilities to improve the outcome of ALL in Mosul City.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.